Abstract
Purpose
No occupational exposure limit exists for antineoplastic drugs. The main objective of this study was to describe environmental contamination with cyclophosphamide, ifosfamide and methotrexate in pharmacy and patient care areas of Canadian hospitals in 2012. The secondary objective was to compare the 2012 environmental monitoring results with the 2008–2010 results.
Methods
Six standardized sites in the pharmacy and six sites on patient care areas were sampled in each participating center. Samples were analyzed for the presence of cyclophosphamide, ifosfamide and methotrexate by UPLC-MS-MS. The limit of detection (LOD) was 1.8 pg/cm2 for cyclophosphamide, 2.2 pg/cm2 for ifosfamide and 8.0 pg/cm2 for methotrexate. The comparison of surface contamination between the 2008–2010 and 2012 studies was made with the 75th percentile of cyclophosphamide concentration.
Results
A total of 33 hospitals participated in the study and 363 samples were collected. Overall, 40 % (147/363) of the samples were positive for cyclophosphamide, 18 % (68/363) were positive for ifosfamide and 5 % (17/363) were positive for methotrexate. In 2012, the 75th percentile value of cyclophosphamide surface concentration was of 9.4 pg/cm2, which is four times lower than the 2008–2010 75th percentile of 40 pg/cm2. In both studies, the 75th percentile for ifosfamide and methotrexate concentration was lower than the LOD.
Conclusions
Surface contamination by cyclophosphamide, ifosfamide and methotrexate in Canadian hospitals is improving both in terms of the proportions of positive samples and in terms of the surface concentration of antineoplastic drugs. A local 75th percentile value should be use to assess local contamination and interpret local results.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Society of Health-System Pharmacists (2006) ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm 63: 1172–1193. http://www.ashp.org/s_ashp/docs/files/BP07/Prep_Gdl_HazDrugs.pdf. Accessed 21 Sept 2012
American Society of Hospital Pharmacists (1990) ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 47:1033–1049
Association paritaire pour la santé et la sécurité au travail, secteur des affaires sociales (2008) Prevention guide—safe handling of hazardous drugs. http://www.asstsas.qc.ca/publications/publications-specialisees/guides-de-prevention/prevention-guide-safe-handling-of-hazardous-drugs.html. Accessed 21 Sept 2012
Bussieres JF, Tanguay C, Touzin K, Langlois E, Lefebvre M (2012) Multicenter study of environmental contamination with hazardous drugs in Quebec hospitals. Can J Hosp Pharm 65(6):428–435
Bussières JF, Tanguay C, Lefebvre P (2011) Perspective québécoise et canadienne de la pratique pharmaceutique en établissement de santé 2009–2010. Pharmactuel 44(2):122–152
Chu WC, Hon CY, Danyluk Q, Chua PP, Astrakianakis G (2012) Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning. J Oncol Pharm Pract 18(1):46–51
Cocker J, Jones K, Morton J, Mason HJ (2007) Biomonitoring at the UK health and safety laboratory. Int J Hyg Environ Health 210(3–4):383–386
Connor TH, DeBord DG, Pretty JR, Oliver MS, Roth TS, Lees PS, Krieg EF Jr, Rogers B, Escalante CP, Toennis CA, Clark JC, Johnson BC, McDiarmid MA (2010) Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J Occup Environ Med 52(10):1019–1027
Harding J (2010) Drug distribution systems. In: Hall K et al. Hospital pharmacy in Canada 2009/2010 Report. http://www.lillyhospitalsurvey.ca/hpc2/content/rep_2010_toc.asp. Accessed 04 Oct 2012
Hedmer M, Tinnerberg H, Axmon A, Jönsson BA (2008) Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health 81(7):899–911
Hornung RW, Reed LD (1990) Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg 5(1):46–51
International Society of Oncology Pharmacy Practitioners Standards Committee (2007) ISOPP standards of practice. J Oncol Pharm Pract 13(Suppl):1–81
Larson RR, Khazaeli MB, Dillon HK (2002) Monitoring method for surface contamination caused by selected antineoplastic agents. Am J Health Syst Pharm 59(3):270–277
National Institute for Occupational Safety and Health (2004) Preventing occupational exposure to antineoplastic and other hazardous drugs in healthcare settings. Cincinnati OH: U.S. Department of Health and Human Services, Centers for Disease Control, National Institute for Occupational Safety and Health, DHHS. http://www.cdc.gov/niosh/docs/2004-165/. Accessed 21 Sept 2012
National Institute of Occupational Safety and Health (2012) NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2012. http://www.cdc.gov/niosh/docs/2012-150/. Accessed 21 Sept 2012
Official Journal of the European Union (2009) Commission directive 2009/90/CE of 31 July 2009. Article 5: calculation of mean values. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:201:0036:0038:EN:PDF. Accessed 04 Oct 2012
Ordre des pharmaciens du Québec. Groupe de travail sur les préparations magistrales stériles et non-stériles en pharmacie (2012) Norme sur les préparations magistrales stériles (projet) http://prod.opq.org/documents/Norme%20Mag%20steriles%20__110224_CONSULTATION.PDF. Accessed 24 sept 2012
Schierl R, Bohlandt A, Nowak D (2009) Guidance values for surface monitoring of antineoplastic drugs in German pharmacies. Ann Occup Hyg 53(7):703–711
Sessink PJ, Connor TH, Jorgenson JA, Tyler TG (2011) Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Pract 17(1):39–48
Siderov J, Kirsa S, McLauchlan R (2010) Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device. J Oncol Pharm Pract 16(1):19–25
Sottani C, Turci R, Schierl R, Gaggeri R, Barbieri A, Violante FS, Minoia C (2007) Simultaneous determination of gemcitabine, taxol, cyclophosphamide and ifosfamide in wipe samples by high-performance liquid chromatography/tandem mass spectrometry: protocol of validation and uncertainty of measurement. Rapid Commun Mass Spectrom 21(7):1289–1296
Stover D, Achutan C (2011) Occupational exposures to antineoplastic drugs in an Oncology-Hematology Department. J Occup Environ Hyg 8(1):D1–D6
US Pharmacopeia (2004) USP <797> guidebook to pharmaceutical compounding—sterile preparations. In: The United States pharmacopeia, 28th rev., and The national formulary, 23rd edn. The United States Pharmacopeial Convention, Rockville, 2461–2477
Acknowledgments
The authors would like to thank the 33 healthcare centers that participated in the 2012 study.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Merger, D., Tanguay, C., Langlois, É. et al. Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals. Int Arch Occup Environ Health 87, 307–313 (2014). https://doi.org/10.1007/s00420-013-0862-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00420-013-0862-0